沙利度胺联合常规化疗治疗多发性骨髓瘤的临床效果及安全性

Clinical effect and safety of thalidomide combined with conventional chemotherapy on multiple myeloma

目的探讨沙利度胺联合常规化疗治疗多发性骨髓瘤的临床效果及安全性。方法回顾性选取我院2015年1月至2020年1月收治的100例多发性骨髓瘤患者,依据治疗方法将其分为常规化疗组(n=50,常规化疗)和沙利度胺组(n=50,常规化疗+沙利度胺)。比较两组的治疗效果。结果治疗后,沙利度胺组的M蛋白、β2-微球蛋白、骨髓瘤细胞、IL-6、TGF-β水平及CD4^+CD25^+明显低于常规化疗组,血红蛋白水平、INF-γ/IL-10明显高于常规化疗组(P<0.05)。沙利度胺组的治疗总有效率为82.0%,明显高于常规化疗组的66.0%(P<0.05)。两组患者各项不良反应发生率比较,差异均不显著(P>0.05)。结论沙利度胺联合常规化疗治疗多发性骨髓瘤的临床效果显著,安全性高,值得临床推广应用。

Objective To investigate the clinical effect and safety of thalidomide combined with conventional chemotherapy on multiple myeloma.Methods A total of 100 patients with multiple myeloma admitted in our hospital from January 2015 to January 2020 were selected retrospectively,and the patients were divided into conventional chemotherapy group(n=50,conventional chemotherapy)and thalidomide group(n=50,conventional chemotherapy+thalidomide)according to the treatment method.The therapeutic effects of the two groups were compared.Results After treatment,the levels of M protein,β2-microglobulin,myeloma cells,IL-6,TGF-βand CD4^+CD25^+in the thalidomide group were significantly lower than those in the conventional chemotherapy group,while hemoglobin level and INF-γ/IL-10 in the thalidomide group were significantly higher than those in the conventional chemotherapy group(P<0.05).The total effective rate of treatment in the thalidomide group was 82.0%,which was significantly higher than 66.0%in the conventional chemotherapy group(P<0.05).There were no significant differences in the incidences of adverse reactions between the two groups(P>0.05).Conclusion Thalidomide combined with conventional chemotherapy in the treatment of multiple myeloma has a significant clinical effect and high safety,which is worthy of clinical promotion and application.